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Abstract
Background: Asthma and chronic obstructive pulmonary disease (COPD) are frequent in the general population.
These diseases can worsen the quality of life of people suffering from them, limiting their daily activities and
disrupting their sleep at night. Some questionnaires to measure the impact of the diseases on the daily life of
patients are available. The measurements of subjective outcomes have become a part of clinical practice, and are
used very frequently in clinical trials. Our aim was to describe how data on HRQoL in asthma and COPD are
reported in papers published in the medical literature.
Methods: We identified papers on the recent respiratory drugs (chemical, not biological), that reported the HRQoL
measurement and that were published from 2009 to April 2014. We planned to describe data about HRQoL, and
we had no intention of comparing the degree of efficacy of drugs.
Results: The most used questionnaires are the Asthma Quality of Life Questionnaire (AQLQ) and the Saint George's
Respiratory Questionnaire (SGRQ). These tools, administered at the baseline and at the end of the study (and
interim evaluations in the longer studies) allowed for the identification of improvements as perceived by the
patient after the treatment, even if in some cases these improvements were limited and not clinically relevant.
Subjective measurements have always been placed among the secondary endpoints and the number of patients
(estimated for the main endpoint) has often statistically overestimated the result. In addition, it is clear that
subjective data is normally reported, but rarely commented on.
Conclusions: There are some methodology aspects that should be discussed in more depth, for example the
necessity to express variations in the subjective perception, not as p-value but as effect-size.
Keywords: Asthma, COPD, Asthma quality of life questionnaire, Health-related quality of life, Saint George's
respiratory questionnaire
Background
Asthma and chronic obstructive pulmonary disease
(COPD) are frequent in the general population. The
prevalence of asthma is estimated to be between 1 and
18 % of the population in the countries where it has been
studied [1], whereas COPD affects about 6 % of the adult
population, with a higher prevalence in older age groups
[2]. These diseases are characterised by a narrowing of the
bronchi associated with chronic inflammation. However,
there are some differences between asthma and COPD in
terms of onset age, causal factors, clinical aspects and
impact on daily life. Functional measurements are used to
measure severity and reversibility of the pulmonary ob-
struction. However, the relationship between pulmonary
obstruction, dyspnea and impact of the disease on the
daily life of the patient, is not necessarily linear [3]. The
subjective data obtained from the patients can be useful
for supplementing clinical and instrumental data and en-
abling the physician to identify any change (improvements
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or worsening) in the state of health, as perceived by the
patient, thus allowing for an adjustment of the treatment.
Questionnaires do exist and have been used for decades as
they can gather data, in a standardised form, about the
patients’ perception of the status of the disease and/or the
received medical treatments. This information, report-
ed directly by the patient without other people’s
interpretation, about his/her well-being, behaviour and
feelings as regards his/her state of health and the related
treatments, is defined as Patient-Reported Outcome
(PRO) [4]. The Health-related Quality of Life (HRQoL) is
a well known PRO. We have had available for some time
questionnaires that are used for measuring HRQoL.
European and USA regulatory authorities have published
official guidance documents that reflect their position on
this topic. The USA Food and Drug Administration
(FDA) prepared a formal “Guidance for Industry” which
describes its position on the PROs and informs the
pharmaceutical industry on how it intends to review and
evaluate the PRO tools that are used to support label
claims [5]. The European Medicine Agency (EMA) docu-
ment points out the role that the HRQoL may play in the
development process of a medicinal product, by simply
providing some recommendations on their use [6].
Recently, a number of new medicinal products to be
used alone or in fixed combinations have been
registered for the treatment of asthma and/or COPD.
In many clinical studies of these drugs, HRQoL
measurements were included.
Our aim was to deepen the knowledge on how the
measurement of HRQoL was carried out for supporting
the registration of these drugs (medicinal products of
chemical and not biological origin). We planned to
review the papers in order to describe and comment on
the used tools, the results of the measurements and the
use of the HRQoL data that were obtained. We had no
intention to comment on the degree of efficacy of the
medicinal products being considered.
Review
We took into consideration the respiratory drugs that
were launched in the last years. We described
randomised and controlled clinical trials of medicinal
products developed for asthma and for COPD, published
from 2009 to the spring of 2014. The year 2009 was
chosen because in that year the National Health Service
in England (NHS) made the decision to measure the
impact, as perceived by the patient, of some thera-
peutic procedures [7]. Non-randomised studies, post-hoc
analyses, meta-analyses and/or systematic reviews of
respiratory medicinal products have not been taken into
account. For each study, the design, sample size, use of
tools for the measurement of PROs have been identified
and the related data briefly described. No statistical
analyses of any type were carried out; in fact this report
consists exclusively in a description of the findings.
Thirty four articles, published in the considered period,
were analysed (see Tables 1 and 2). Eleven studies were on
asthma. The questionnaire used in these studies was the
Asthma Quality of Life questionnaire (AQLQ). The
AQLQ is a 32 items questionnaire in 4 domains (symp-
toms, activity limitation, emotional function and environ-
mental stimuli). It is suitable for adult with asthma, that
should respond on a 7 point scale. Psychometric tests
show that a change in score of 0.5 is the smallest change
that can be considered clinically important (this means
that the patient appreciates the change in his/her health
condition).
Twenty three studies were on COPD. The questionnaire
they used was the Saint George's Respiratory Question-
naire (SGRQ). It is a 50 items questionnaire designed to
measure impact on overall health, daily life and perceived
well-being in patients with COPD. Higher scores indicate
more limitations. A mean change score of −4 units is
considered as clinically important.
Only 3 studies on asthma reported a change that was
statistically significant (27 % of the studies), and only 2
(18 % of the studies) reported the percentage of patients
who reached the clinical significance (at least 0.5 change
from baseline). The clinical significance ranged between
55.0 and 66.7 % of patients. Among studies on COPD,
16 (69.5 %) reported a statistical significance and 17
(80 %) reported the percentage of patients with the
clinical significance (at least −4 units from baseline).
The clinical significance ranged between 21.9 and 59.4 %
of patients.
Usually, the authors describe in a very short way
HRQoL results, and poor details are reported.
Conclusions
A description of the literature about respiratory, non-
biological medicinal products, developed in the past few
years, has allowed to highlight that the PRO measure-
ment has been often included in the studies’ proto-
cols. This is in line with the recognition by regulatory
authorities, payers and pharmaceutical companies that
measurement of the patient experience with the drug
is increasingly important. In all the measurements ob-
served, the subjective data was considered a second-
ary endpoint. This is consistent with the endpoint
hierarchy established by EMA and the FDA which
sees the physiological effect produced by the study drug as
a priority, and relegates the PRO to a secondary endpoint.
The choice of tools to be used meets the specifications
of the reference documents. AQLQ is used with the
patients with asthma, whereas the SGRQ is used with
the patients with COPD. Both tools have been well
documented since their initial development, and are
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validated and available in many languages [8, 9]. In all
the studies, the time frame for the administration of the
questionnaires is specified. In the shorter studies, the
measurements are reported at the baseline and at the
end of the study. In longer studies, there can be interim
measurements. It should be noted that the short
duration of a study (in particular in the COPD case) is
planned to allow for functional measurements, but it
could not capture the impact that the drug has on the
health, as perceived by the patient. For instance, Kerwin
Table 1 Studies on asthma
Drugs Baseline Final score Statistical significancea Clinical significance Reference
flut/form 500/20 μg 4.42 ± 0.89 5.34 ± 1.07 P = 0.036 Bodzenta-Lukaszyk et al.
Resp Med 105 674-682
2011 [13]flut + form 500 + 24 μg 4.57 ± 0.99 5.30 ± 1.00
flut/form250/10 μg Not reported Mean improvement of 0.8
in both treatment groups
ns 55 % Bodzenta-Lukaszyk et a.l
Journal of Asthma 49(10),
1060-1070, 2012 [14]bud/form400/12 μg 57.6 % ns
flut/form combo 4.8 ± 1.1 5.5 ± 1.1 ns Not available Bodzenta-Lukaszyk et al.
Current Medical Research
and Opinion 29, 5 579-588,
2013 [15]
flut + form 4.9 ± 1.2 5.6 ± 1.0
Tio 5 μg add on 4.8 in all groups Change of 0.1 points for
both active treatments
compared with placebo
ns Not available Kerstjens et al. Journal of
Allergy Clin Immunol 128,
2 308-314, 2011 [16]Tio 10 μg add on
Plac add on
Trial 1 Not achieved Kerstjens et al. New England
Journal of Medicine
367:1198-1207, 2012 [17]Tio 5 μg/die add on 4.6 ± 1.1 5.15 Ns
plac add on 4.6 ± 1.1 5.1 Ns (p < 0.05 al week 24
Trial 2
Tio 5 μg/die add on 4.6 ± 1.0 5.1
plac add on 4.7 ± 1.1 4.93





Louis R et al. The International
Journal of Clinical Practice 63,
10 1479-1488, 2009 [18]Conventional best practice 4.78 4.82
Tio 5.58 P = 0.01 Not available Peters et al. New England
Journal of Medicine 363
18 1715-1726, 2010 [19]Double glucocorticoid 5.43 ± 1.05 5.48 P = 0.38
salm 5.71 P < 0.001
Flut fur/vil 200/25 μg Not available Baseline + 0.93 ± 0.065 ns Not available O’Byrne et al. Eur. Resp.
Journal 43 773-782,
2014 [20]Flut fur.200 μg Baseline + 0.88 ± 0.071
Flut prop.500 μg Baseline + 0.90 ± 0.068
Flut. fur/vil 100/25 μg 5.35 5.85 ns 46 % Woodcock et al. Chest 144(4),
1222-1229, 2013 [21]
flut. pro/salm 250/50 μg 5.37 5.79 38 %
salm 50 μg 5.175 Baseline + 0.280 ns Not available Bateman et al. J. Allergy Clin
Immunol128, 315-322,
2011 [22]tio 5 μg Baseline + 0.131
plac Baseline + 0.039 Not available
Adjustable bud/form AQLQ AQLQ AQLQ AQLQ O’Connor et al. Journal of
Asthma 47 217-223,
2010 [10]Fixed bud/form Not available Not available P < 0.04* 66.7 %





bFixed-dose regimen baseline vs end of treatment
*Adjustable dosing vs fixed dose regimen
p ≤ 0.002 vs fluticasone propionate/salmeterol
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Table 2 Studies on COPD
Drugs Baseline SGRQ Final score Statistical significancea Clinical significance Reference
Aclid 200 μg 45.9 -4.7 vs baseline P = 0.013 vs plac. 49 %* Kerwin E.M., et al. COPD
patients (ACCORD COPD I).
COPD 9 90-101, 2012 [23]Aclid 400 μg 48.3 -4.5 vs baseline P = 0.019 vs plac. 45 %
plac 45.1 - 2 vs baseline 36 %
Aclid 200 μg 46.3 ± 16.8 .-3.8 ± 1.1 vs plac P < 0.001vs plac 56.0 %** Jones P.W., et al. Eur Resp
Journal 40 830-836, 2012 [11]
Aclid 400 μg 47.6 ± 17.7 -4.6 ± 1.1 P < 0.0001 vs 57.3 %**
plac 45.1 ± 15.8 plac. 41.0 %
Aclid 200 μg 48.5 -5.3 vs baseline ns 41-6 % - 46.6 % Gelb A.F., et al. Respiratory
Medicine 107 1957-1965,
2013 [24]Aclid 400 μg 49.8 -5.2 vs baseline 45.2 % - 49.1 %
Glycopyr 50 μg 46.11 39.50 P = 0.004 56.8 % D’Urzo A., et al. Respiratory
Research 12 156, 2011 [25]
Plac 46.34 42.31 46.3 %
P = 0.006
Glycopyr 50 μg Not -3.32 vs placebo P < 0.001 54.3 % Kerwin E., at al. European
Respiratory Journal 40
1106-1114, 2012 [26]Tio 18 μg reported -2.84 vs placebo P = 0.014 59.4 %
Plac 50.8 %
Indac 300 μg 43 -4.7 vs placebo P < 0.001 vs plac Not reported Dahl R. et al. Thorax 65
473-479, 2010 [27]
Indac 600 μg 44 -4.6 vs placebo
Form 44 -4.0 vs placebo
Plac 43
Indac 150 μg 43 ± 18.6 -5.0 vs baseline P < 0.001 52.8 %** Kornmann O. et al. European
Respiratory Journal 37 273-279,
2011 [28]Salm 50 μg 44. ± 18.4 -4.1 vs baseline P < 0.001 48.6 %***
plac 44 ± 18.1 38.0 %
Indac 150 μg Not reported -3.3 vs placebo**** P < 0.001 vs plac - Donohue J.F. et al. Am J Respir
Crit Care Med 182 155-162,
2010 [29]Indac 300 μg -2.4 vs placebo P < 0.01 vs plac
Tio 18 μg -1.0 vs placebo Ns vs plac
plac
Indac 150 μg 42.3 ± 17.60 37.1 ± 0.56 P < 0.001 50.5 % Buhl R. et al. Eur Respir J 38
797-803, 2011 [30]
Tio 18 μg 42.7 ± 18.04 39.2 ± 0.55 42.5 %
p≤ 0.001
Indac 150 μg 47.9 42.3 P = 0.73 49 % Decramer M.L. et al. Lancet
Respir Med 1 524-533, 2013 [31]
Tio 18 μg 48.7 42.2 49 &
Tio 5 μg Not reported -4.7 vs baseline P < 0.0001 49.5 % Bateman E.D. et al. Respiratory
Medicine 104, 1460-1472,
2010 [32]P lac -1.8 vs baseline 41.4 %
P < 0.0001
Tio 18 μg emphysema 46.7 ± 3.0 39.4 ± 2.7 ns Not reported Fujimoto K. et al. International
Journal of COPD 6, 219-227,
2011 [33]Tio 18 μg non emphys 35.1 ± 6.4 26.9 ± 4.6
Salm 50 μg emphysema 38.6 ± 3.5 33.0 ± 3.2
Salm 50 μg nonemphys 37.5 ± 8.5 29.3 ± 7.4
Tio 18 μg 46.1 ± 19.1 -4.5 vs baseline P < 0.05 Not reported Hoshino M. et al Respirology 16
95-101, 2011 [34]
Tio + Salm/flut 50/250 μg 42.7 ± 17.0 -10.2 vs baseline
Umec 62.5 μg Not reported -3.14 vs baseline P < 0.001 both doses of
umeclidinium vs placebo
Not reported Trivedi R. et al. Eur Respiratory J
43 72-81, 2014 [35]
Umec 125 μg -6.12 vs baseline
Plac +4.75 vs baseline
Beclom/form 100/6 μg 60.4 ± 19.5 -3.75 ± 13.91 ns 25.40 %
Bud/form 200/6 μg 57.2 ± 18.6 -4.28 ± 11.92 21.90 %
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reports, in the conclusions of his study, that a duration
above 12 weeks could have allowed the patients treated
with aclidinium 400 μg to reach the Minimal Clinical
Important Difference (MCID) in a significantly greater
percentage compared with the patients receiving placebo
[10]. A further aspect for consideration is the use of the
placebo treatment arm. These patients may receive
rescue treatment, and often the variation in the SGRQ
score obtained with these patients is important, as is the
percentage of responder patients (those who reach the
MCID). Another aspect noted in some studies was that
the improvement reported with the SGRQ was in
contrast with the bronchodilator effect. For example,
Jones et al point out this aspect in the placebo arm of
their study where the spirometry values decline, but the
patients report a better respiratory state of health [11].
The measurements are always accompanied by infor-
mation on their statistical significance. With reference
to this point, we noted that more COPD than asthma
studies reported a statistical significance. In other
words, it seems that COPD drugs are significantly
more effective than asthma drugs. Furthermore, it is to
Table 2 Studies on COPD (Continued)
Calverley P.M.A. et al. Respiratory
Medicine 104 1858-1868,
2010 [36]
Form 12 μg 59.5 ± 20.2 -2.90 ± 13.28 25.30 %
Tio + bud/form Not reported -3.8 vs baseline P = 0.023 49.5 % Welte T. et al. Am J Respir Crit
Care Med 180 741-750, 2009 [37]
Tio + plac -1.5 vs baseline 40.0 %
P = 0.016
Bud/form 320/9 μg 55.9 (17.6) -7.2 (1.18) vs bas. ns Sharafkhaneh A. et al. Respiratory
Medicine 106, 2257-268 2012 [38]
Bud/form 160/9 μg 57.8 (16.7) -5.5 (1.17) vs bas.
Form 9 μg 58.6 (16.9) -5.9 (1.17) vs bas.
Indac/Glycopyr
110/50 μg
42.01 35.45 ns 55.5 % Vogelmeier C.F. et al. Lancet
Respir Med 1 51-60, 2013 [39]
Salm/flut 50/500 μg 42.72 36.68 49.1 %
Indat/Glycopyr
110/50 μg
53 (18) 43.8 glycop/indacat 57 % Wedzicha J.A. et al. Lancet Respir
Med 1 199-209, 2013 [40]
Glycopyr 50 μg 52 (18) 45.8 P = 0.0067 e 52 %
Tio 18 μg 52 (17) 46.0 P = 0.00037 vs competitors 51 %
Glycopir/indacat
p = 0.055 e p = 0.051
vs competitors
Indac 150 μg + Glycopyr
50 μg
Not reported - 6.22 (11.47) ns 56.5 % Vincken W. et al. Int Journal of
COPD 9 215-228, 2014 [41]
Indac 150 μg - 4.13 (10.38) vs
baseline
46.8 % ns
Beclom/form 200/12 μg 47.0 (16.7) -5.92 P = 0.08 45.0 % Singh D. et al. BMC Pulmonary
Medicine 14 43 2014 [42]
Flutic/salm 500/50 μg 45.2 (16.5) -3.80 36.2 %
ns
Umec/Vil 62.5/25 μg Not reported -8.07 (0.749) p≤ 0.001 vs 49 % Donohue J.F. et al. Respiratory
Medicine 107 1538-1546,
2013 [43]Umec 62.5 μg -7.25 (0.753) placebo 44 %
Vil25 μg -7.75 (0.760) 48 %
Plac -2.56 (0.950) vs
baseline
34 %
Umec/Vil125/25 μg Not reported 40.10 (0.665) Combination 49 % Celli B. et al Chest 145 (5)
981-991, 2014 [44]
Umec125 μg 43.38 (0.664) p≤ 0.001 vs umec e 40 %
Vil 25 μg 42.82 (0.681) p <0.01 vs 41 %
Plac 43.69 (0.875) vilanterol 37 %
aBetween groups
*p < 0.005 vs placebo
**p < 0.001 vs placebo
***p < 0.01
****p < 0.01 vs tiotropium
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consider that a number of COPD studies foresaw the ana-
lysis versus a placebo arm, and the number of
patients could be excessive for the HRQoL measure-
ment. With reference to the clinical significance, asthma
patients have a higher percentage of patients who expe-
rienced a clinically important change than COPD
patients (despite the lower number of measurements).
We can speculate that asthma patients perceive better
the changes given by drugs than COPD patients. On
the other hand, asthmatics are generally younger than
COPD patients, and suffer less from other diseases
(comorbidities). However, the subjective nature of the
measurements should lead to some considerations on the
significance of the effects produced by the treatment.
Usually, the variations in the scores obtained from the
questionnaires on HRQoL are assessed on an effect-size
basis, since a change produced by a treatment may be
statistically significant (possibly because the number of
patients calculated for the main endpoint is high), but it
may not be perceived as clinically significant by the
patients. In general, effect-size indexes have been
developed for the exact purpose to avoid making incorrect
inferences, due also to high sample sizes. In other words,
since the above indicated indexes seek to square the
results net of the effects of the sample (number of
subjects), they should not be affected by this data. The
effect-size indexes allow for an evaluation of the amplitude
of an effect in each research design, but there always re-
mains the difficulty of choosing the most appropriate
index and interpreting the results. Perhaps the latter is the
reason why measurement results are usually reported
without comments. In some cases, PRO measurement
data are included in the discussion, but in many other
cases, they are only briefly mentioned.
Undoubtedly, the PRO adds knowledge to the drug.
Within the respiratory area, there are many medicinal
products available which have demonstrated their
efficacy in intervening on the two main characteristics
that define asthma and COPD, i.e. bronchoconstriction
and chronic inflammation. However, only some of them
provide information about the outcomes of treatment
which may be important to patients. This data could
represent a discriminatory factor in the choice of the
medicinal products to be included into a formulary. In
fact, a medicinal product that is perceived as useful by
the patient could have more probability to be taken
(good adherence to treatment) and this would maximise
the financial investment of the third party payer. Among
the cited studies, one has used the Onset of Effect
Questionnaire (OEQ) to measure the preference of the
patient with asthma of a certain bronchodilator versus
another bronchodilator in the same pharmacological
category, but slower in manifesting its effects [10]. The
fact that this questionnaire was not used in other studies
may mean that it is not important to measure this
parameter, or that the questionnaire was used in that
study just to reiterate that one of the drugs was faster in
manifesting its effects.
Some studies, not included in this analysis because
they were published before 2009, measured the pref-
erences of the patients regarding the inhaler used.
Dalby et al cite these experiences in one article that
discusses the development of an inhaler [12]. This
measurement can be useful also if the intent is to
provide the patient with a treatment, that, on average,
he/she will consider satisfactory and therefore, pre-
sumably, be more willing to adopt.
To conclude, the subjective measurements, initially
reserved for patients with very serious diseases and a lim-
ited life expectancy, have become more commonly used
even with patients suffering from chronic diseases. The
fact that patients with asthma and COPD can have a lon-
ger life expectancy makes the quality of those years left to
live very important. It is therefore desirable that the PRO
measurements be increasingly used and become part of
the daily routine of clinical practice. In this perspective,
tools such as the SGRQs might be considered labour-in-
tensive requiring too long for their completion and
interpretation. To this end, some other easier and
simpler tools could be proposed for development.
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